Theraly Fibrosis, a TEDCO portfolio company, awarded $3.9 Million SBIR Phase II grant to support the development of TLY012 for Chronic Pancreatitis

Theraly Fibrosis, a preclinical-stage biotechnology company focused on development and commercialization of drugs for various fibrotic diseases today announced the company has been awarded a Small Business Innovation Research (SBIR) Phase II grant by the National Institutes of Health (NIH) in the amount of $3.9 million to support development of TLY012 for treatment of chronic pancreatitis.